Summary & Overview
HCPCS Level II M0245: Intravenous Infusion of Bamlanivimab and Etesevimab
HCPCS Level II code M0245 represents the intravenous infusion of bamlanivimab and etesevimab and includes both the infusion procedure and post-administration monitoring. This code matters nationally because it standardizes billing for a specific monoclonal antibody combination used in outpatient infusion settings, ensuring consistent reporting and payment for the full encounter that includes observation after administration. Payers evaluated in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find concise benchmarks and clinical context for use of M0245, including typical sites of service and the service line implications for outpatient infusion centers. The summary covers common billing considerations, such as inclusion of monitoring time within the code and potential implications for claim submission across major commercial payers and Medicare. The publication highlights policy and reimbursement elements relevant to coding accuracy, documentation to support the bundled infusion-and-monitoring descriptor, and how this code fits into outpatient infusion workflows. Data not available in the input where payer-specific rates, associated taxonomies, ICD-10 mappings, and related codes would normally be listed.
Billing Code Overview
HCPCS Level II code M0245 describes an intravenous infusion of bamlanivimab and etesevimab, and explicitly includes the infusion procedure and post-administration monitoring. The service type is an intravenous monoclonal antibody infusion for administration of the combined therapy. The typical site of service is an outpatient infusion center or other outpatient clinic setting where intravenous biologic therapies and post-infusion observation are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with multiple comorbidities (type 2 diabetes, chronic kidney disease stage 3, and obesity) presents to an outpatient infusion center within the early symptomatic window after a confirmed positive SARS-CoV-2 NAAT test. The patient meets emergency use criteria for treatment with the combined monoclonal antibody regimen bamlanivimab and etesevimab. After telephonic pre-screening for allergy history and anticoagulation status, the patient arrives for same-day intravenous infusion.
The clinical workflow includes: pre-infusion nursing assessment (vitals, symptom review, medication reconciliation), verification of indication and consent by the ordering clinician, pharmacy preparation and verification of M0245 product and dose, IV access placement, administration of the infusion over the recommended infusion time, continuous monitoring for infusion-related reactions, post-infusion observation for an appropriate monitoring period, documentation of drug lot number and administration times, and discharge instructions. The service includes the infusion and post-administration monitoring as described by the billing code M0245.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to safely administer or monitor the infusion is substantially greater than typical due to complexity or complications during the encounter. |